A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Anticoagulants

  • Xarelto (Rivaroxaban): FDA Approved for DVT and PE Treatment

    Stephan Moll, MD writes… Today is a very exciting day for patients and health care professionals: the oral anticoagulant Xarelto® (rivaroxaban) was FDA approved today (Nov 2nd, 2012) for the use in patients with DVT and PE – for the acute treatment of DVT and PE, as well as for the secondary long-term prevention of…

  • Argatroban Nomogram

    Stephan Moll, MD writes…. The treatment of heparin induced thrombocytopenia may require the use of argatroban. Here is the argatroban nomogram  used at our institution, the University of North Carolina (UNC) at Chapel Hill. Disclosure: I have no financial disclosures relevant to this post. Last updated: June 25th, 2013

  • Aspirin Prevents Recurrent DVT and PE – WARFASA Study

    Stephan Moll, MD writes… A clinically very relevant study (WARFASA) published today (May 24, 2012) in the New England Journal of Medicine [ref 1] shows that aspirin, 100 mg per day, reduces the risk of recurrent venous thromboembolism (VTE) in patients with unprovoked (= idiopathic) VTE, who have completed 6 to 18 months of anticoagulant therapy, without…

  • Rivaroxaban (Xarelto) and PE

    Stephan Moll, MD writes… Good news: The large phase 3 clinical trial comparing 3-12 months treatment of Rivaroxaban (Xarelto) with warfarin in patients with newly diagnosed pulmonary embolism was published on 3-26-2012 in the New England Journal of Medicine [reference 1], showing that Rivaroxaban was (a) noninferior to warfarin in its efficacy, (b) caused the…

  • New ACCP Guidelines – DVT and PE: Highlights and Summary

    Stephan Moll, MD writes…  This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here

  • New ACCP Guidelines

    Quick note: New ACCP (American College of Chest Physicians) guidelines on antithrombotic therapy published today:   http://www.chestnet.org/accp.

  • Alcohol and Warfarin or Pradaxa

    A patient may ask: “I am on warfarin.  Is it o.k. for me to drink alcohol?  Does alcohol intake increase the INR?”   Does drinking alcohol change the INR in the patient on warfarin?

  • Blood or Organ Donation: The Patient on Anticoagulants or with Thrombophillia

    A patient may ask:  “I am on warfarin – can I donate blood?”  Your answer:  “No”.  A person on an anticoagulant will not be accepted as a blood donor